Rivaroxaban

Rivaroxaban is the first orally active anticoagulating and antithrombotic agent and a direct factor Xa inhibitor.  It is used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) and also used as thrombosis prophylaxis in specific situations. Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease.

Therapy Area: Medicine
Form: Oral tablet
Packaging: 1x15, 1x10, 1x10 tablets

COMPOSITION:

Rivaroxaban 10mg, 15mg,20mg

MODE OF ACTION:

Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible

INDICATIONS

  • Deep vein thrombosis (DVT)
  • Pulmonary embolism (PE)
  • Thrombosis prophylaxis
  • Venous thromboembolic events (VTE) prevention
  • Non-valvular atrial fibrillation and stroke prophylaxis

Dosage

IndicationDosage and Administration
Non-valvular Atrial Fibrillation

&

Stroke prophylaxis

20 mg once daily with the evening meal
Acute VTE treatment15 mg twice daily with food for three weeks;

then 20 mg once daily with food

VTE primary prevention10 mg once daily, with or without food

No dosage adjustment necessary in patients with CrCl >50 mL/minute

Disclaimer:

This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.

Enquire About Rixavin 10/15/20

Fill the form below and we will get in touch with you

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.